Orihara, K., Narita, M., Tobe, T., Akasawa, A., Ohya, Y., Matsumoto, K., et al. (2007) Circulating FoxP3+CD4+ Cell Numbers in Atopic Patients and Healthy Control Subjects. Journal of Allergy and Clinical Immunology, 120, 960-962.
https://doi.org/10.1016/j.jaci.2007.05.036

has been cited by the following article:

• TITLE: The Role of Cytokine Interleukin-2, Transcription Factor of FoxP3 in the Immunological Regulation of Allergic Rhinitis

  AUTHORS: Bambang Suprayogi Resi Utomo, Mochammad Hatta, Robert H. Sirait, Sutji Pratiwi, Muhammad Nasrum Massi

  KEYWORDS: Allergic Rhinitis, Interleukin-2, FoxP3

  JOURNAL NAME: International Journal of Otolaryngology and Head & Neck Surgery, Vol.7 No.1, January 30, 2018

  ABSTRACT: Allergic rhinitis (AR) is the inflammation of nasal mucosa due to the type 1 hypersensitivity reactions mediated by immunoglobulin E (IgE) and triggered by certain allergens. The latest concept in allergic disease is the role of regulatory T cells (Treg). Interleukin-2 enhances the function and survival of Treg to perform its function as a controller of effector for forming a tolerant system by suppressing and regulating the homeostasis system. Treg has a transcription factor FoxP3 which plays a role in developing major function of Treg and progression to produce IL-10 and TGF-ß. The atopic diseases are caused by a deficiency of Treg. The new perspective is low-dose IL-2 therapy towards autoimmune disease and allergic inflammation. Low-dose IL-2 therapy requires further clinical studies to optimize the dose, time, and the schedule of the IL-2 treatment. FoxP3 has the potential to assist in evaluating the active process of immunological process, which cannot be evaluated by Th1 and Th2 markers, and FoxP3 can be a successful immunotherapy marker.